Lumen to earn up to $14.5 million from CARB-X for antidiarrheal

by admin | Feb 12, 2021 | Press Release

Lumen Bioscience Receives CARB-X Award to Develop Preventative for Deadly Diarrheal Diseases and Details Broad Potential of Spirulina Platform

by admin | Jan 27, 2021 | Press Release

Seattle, WA, January 27, 2021 – Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drug candidates for highly prevalent diseases, today announced initiation of an up to $14.5 million project funded by CARB-X to develop an oral monoclonal...

Lumen bags U.S. grant for GI-focused COVID-19 antibody cocktail

by admin | Nov 23, 2020 | Press Release

Lumen Bioscience reels in $16M Series B to democratize biologics

by admin | Nov 23, 2020 | Press Release

With a $4M federal grant, Lumen jumps into the Covid-19 treatment race

by admin | Nov 23, 2020 | Press Release

Q and A with Lumen: using spirulina to manufacture Covid-19 antibodies

by admin | Nov 11, 2020 | Press Release